Kalaris Therapeutics Inc cash flow to debt ratio of -2.97K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kalaris Therapeutics Inc's free cash flow has increased -36.23% from $-67.70M last year to $-43.18M, signaling increasing performance

Kalaris Therapeutics Inc's debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Kalaris Therapeutics Inc has insufficient data to evaluate this check.

Kalaris Therapeutics Inc has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Kalaris Therapeutics Inc's latest filing, so interest coverage cannot be calculated.

Kalaris Therapeutics Inc has insufficient data to evaluate this check.

Kalaris Therapeutics Inc's short-term assets of $118.81M exceed its short-term liabilities of $9.71M

Kalaris Therapeutics Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kalaris Therapeutics Inc's return on equity of -72.78%, is lower than 15.00%, indicating bad performance

Kalaris Therapeutics Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kalaris Therapeutics Inc had positive net income in only 0 out of 5 years, indicating unstable earnings

Kalaris Therapeutics Inc has negative free cash flow, indicating the company is burning cash rather than generating it

Kalaris Therapeutics Inc has negative free cash flow, indicating cash burn

Kalaris Therapeutics Inc's yearly earnings has increased -26.09% since last year from $-58.77M to $-43.44M, signaling increasing performance

Kalaris Therapeutics Inc's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -46.68% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kalaris Therapeutics Inc has insufficient revenue history to calculate 3-year revenue CAGR.

Kalaris Therapeutics Inc had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Kalaris Therapeutics Inc had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Kalaris Therapeutics Inc has insufficient data to evaluate this check.

Kalaris Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kalaris Therapeutics Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kalaris Therapeutics Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kalaris Therapeutics Inc has insufficient data to evaluate this check.

Kalaris Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kalaris Therapeutics Inc has a price-to-book ratio of 1.36x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Kalaris Therapeutics Inc has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue